34 Recruiting Studies Using Brentuximab Vedotin
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Brentuximab Vedotin
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
📍 Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Classical Hodgkin Lymphoma
View Study & Checklist ➔Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
📍 Lucile Packard Children's Hospital Stanford University — Palo Alto, California
Stage II Childhood Hodgkin Lymphoma
View Study & Checklist ➔A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
📍 James P. Wilmot Cancer Institute, University of Rochester Medical Center — Rochester, New York
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
📍 Children's Hospital of Alabama — Birmingham, Alabama
Recurrent Classic Hodgkin Lymphoma
View Study & Checklist ➔Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Ann Arbor Stage I Hodgkin Lymphoma
View Study & Checklist ➔PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Hodgkin Lymphoma
View Study & Checklist ➔Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
📍 M D Anderson Cancer Center — Houston, Texas
CD30-Positive Neoplastic Cells Present
View Study & Checklist ➔A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
📍 Children's Hospital Colorado — Aurora, Colorado
Hodgkin Disease
View Study & Checklist ➔Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
📍 City of Hope Medical Center — Duarte, California
Classic Hodgkin Lymphoma
View Study & Checklist ➔Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Recurrent Hodgkin Lymphoma
View Study & Checklist ➔Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
📍 Children's Hospital of Alabama — Birmingham, Alabama
Ann Arbor Stage III Hodgkin Lymphoma
View Study & Checklist ➔Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
📍 Central Alabama Research — Birmingham, Alabama
Diffuse Large B-cell Lymphoma
View Study & Checklist ➔Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Adult T-Cell Leukemia/Lymphoma
View Study & Checklist ➔Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
📍 Children's Hospital of Alabama — Birmingham, Alabama
Ann Arbor Stage IIB Hodgkin Lymphoma
View Study & Checklist ➔Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Ann Arbor Stage I Hodgkin Lymphoma
View Study & Checklist ➔Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
📍 Stanford Cancer Institute Palo Alto — Palo Alto, California
Ann Arbor Stage IB Hodgkin Lymphoma
View Study & Checklist ➔Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
📍 Lucile Packard Children's Hospital Stanford University — Palo Alto, California
Hodgkin Lymphoma
View Study & Checklist ➔Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
📍 New York Medical College — Valhalla, New York
Anaplastic Large Cell Lymphoma, ALK-Positive
View Study & Checklist ➔Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
Recurrent Follicular Lymphoma
View Study & Checklist ➔Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
📍 Yale Smilow Cancer Hospital — New Haven, Connecticut
T-Cell Lymphoma
View Study & Checklist ➔A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
📍 Children's Hospital of Alabama — Birmingham, Alabama
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
View Study & Checklist ➔Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
📍 University of Alabama — Birmingham, Alabama
NK-Cell Lymphoma
View Study & Checklist ➔A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
📍 University of Miami — Miami, Florida
Hodgkin Lymphoma
View Study & Checklist ➔Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Recurrent Classic Hodgkin Lymphoma
View Study & Checklist ➔Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
📍 Concord Repatriation General Hospital — Concord, New South Wales
Hodgkin Lymphoma
View Study & Checklist ➔Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
📍 Hospital Regional Alta Especialidad Bajio — León, Guanajuato
Hodgkin Lymphoma
View Study & Checklist ➔Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
📍 City of Hope Medical Center — Duarte, California
Relapsed Classic Hodgkin Lymphoma
View Study & Checklist ➔Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
📍 Stanford University Medical Center — Stanford, California
Mycosis Fungoides
View Study & Checklist ➔Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
📍 MD Anderson Cancer Center — Houston, Texas
Mycosis Fungoides
View Study & Checklist ➔Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
📍 City of Hope Medical Center — Duarte, California
Classic Hodgkin Lymphoma
View Study & Checklist ➔Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
📍 Stanford University - (Stanford Cancer Institute) — Stanford, California
Hodgkin Lymphoma
View Study & Checklist ➔PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy
📍 M D Anderson Cancer Center — Houston, Texas
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
View Study & Checklist ➔BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
📍 University of Miami — Miami, Florida
Hodgkin Lymphoma
View Study & Checklist ➔Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
📍 Rheumatology Clinic, St. Joseph's Health Care — London, Ontario
Diffuse Cutaneous Systemic Sclerosis
View Study & Checklist ➔